ZO Skin Health, Inc. has acquired the worldwide rights to ReFissa as well as its generic equivalent tretinoin from Suneva Medical. Financial terms for the acquisition were not disclosed.

ReFissa is the only US Food and Drug Administration-approved prescription cream with a .05% strength emollient base designed to reduce fine facial wrinkles, correct irregular pigmentation, and smooth substantial skin roughness. A derivative of vitamin A, ReFissa’s® new formulation of tretinoin works in tandem with the ZO Melamix skin lightener to help blend the skin to create a more even skin tone. "By acquiring ReFissa, we are able to offer to all of our physician partners a product with superior anti-aging and skin tone benefits so they can continue to prescribe in accordance with my protocols,” says Zein Obagi, MD, Founder and Medical Director of ZO Skin Health, Inc, in a news release.

 Suneva currently markets Bellafill and ReGenica Skincare in the U.S, Canada, and Hong Kong.